Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

ALERT: Portfolio Change

|Includes: Abeona Therapeutics Inc. (ABEO)

Summary

It's time to take profits on ABEO.

FDA designates ABEO's lead cell therapy candidate, Orphan Drug-tagged EB-101, a Breakthrough Therapy for the treatment of epidermolysis bullosa.  

EB-101 is currently in Phase 2 development.

Shares up almost 20% today, 40% since added to my portfolio. 

My Portfolio to be updated with today's closing price.